Cost effectiveness of transcatheter aortic valve implantation (TAVI) for patients with severe symptomatic aortic stenosis in New Zealand
Patients with severe symptomatic aortic stenosis face a poor prognosis unless they undergo surgical aortic valve replacement (SAVR), yet many are at high risk due to co-morbidity, frailty or anatomical limitations. Clinically TAVI may be an appropriate alternative treatment; however, cost effectiveness requires careful consideration and will impact on funding. We aim to provide economic evidence and budget impact for the role for TAVI in the publicly funded New Zealand health care system.
S. Bhattacharyya, M. Roskruge, S. Haynes, T. Ramanathan, M. Webster, P. Ruygrok
National Health Committee, Auckland
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.
Resource Library Item
This resource is available for registered members of CSANZ.
Click the button below to log in to HeartOne and access this resource. Please note that CPD credit is NOT automatically assigned for accessing resources directly.